How to Join This Clinical Trial - NCTNCT04279847

Learn how to participate in this PHASE1 trial studying an investigational therapy for Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia). Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia). Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied

Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia)

Treatment Being Tested

Investigational treatment

Study Phase

PHASE1 - Early safety study

Enrollment Status

ACTIVE_NOT_RECRUITING

Study Identifier

NCTNCT04279847 - ClinicalTrials.gov Identifier

Sponsored By

Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

• Initial screening to determine eligibility
• Regular study visits and health assessments
• Receiving the study treatment or placebo
• Medical monitoring and follow-up care
• Contributing to medical research that may help others
• Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

• Close medical monitoring by healthcare professionals
• Access to potential new treatments
• Compensation for time and travel (varies by study)
• No-cost study-related medical care
• The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 48 locations. Find a study site near you:

And 38 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia):

1. Review the eligibility criteria with your healthcare provider
2. Contact the study team for a pre-screening interview
3. Schedule an in-person screening visit if eligible
4. Review and sign the informed consent form
5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

• Discover clinical trials before competitors
• Access exclusive contact information
• Track sponsor pipelines and opportunities
• Connect with decision makers directly
• Win more business partnerships